TAM Receptor

2-D08 is a synthetic flavonoid and cell-permeable small ubiquitin-like modifier (SUMO) inhibitor, which also inhibits the Axl target with an IC 50 of 0.49nM.

Mer tyrosine kinase inhibitor

BMS-777607 is a pan-TAMkinase inhibitor with IC 50 values of 3.9Nm, 1.1nM, 1.8nM, and 4.3nM for Met, Axl, Ron, and Tyro3, respectively.

TP-0903 (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM.

TAM kinase inhibitor,highly selective

MET inhibitor

Cabozantinib (XL184, BMS-907351) is an orally bioavailable and potent inhibitor of MET and VEGFR2 with IC 50 values of 1.3nM and 0.035nM, respectively.

R428, as a Axl inhibitor, blocks Axl autophosphorylation on its C-terminal docking site, Tyr821, at nanomolar concentrations[1].

Mer inhibitor,potent and selective

A multi-kinase inhibitor

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.

Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.

SGI-7079 is an Axl inhibitor, significantly inhibits the proliferation of SUM149 or KPL-4 cells with an IC50 of 0.43 or 0.16 uM, respectively.

Gilteritinib is a highly selective and oral FLT3 inhibitor with IC 50 values of 0.29nM and 0.73nM for FLT3 and AXL, respectively.

R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.

Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904.

UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3.

RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity.

An allosteric inhibitor of Akt1/2

XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity. XL092 has the potential for kinase-dependent diseases and conditions research.

UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.

DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.